NASDAQ:MDVN

(MDVN) (MDVN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$81.44
$81.44
50-Day Range
N/A
52-Week Range
$26.41
$81.48
Volume
N/A
Average Volume
3.55 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
MDVN stock logo

About (MDVN) Stock (NASDAQ:MDVN)

Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, pathway which it refers to as MDV4463.

MDVN Stock News Headlines

Notable ETF Outflow Detected - HYLB
These AI trades triggered this morning (545% return)
If you think a market crash is possible in 2024, I don't know why you're not using this yet.
Medivation Alzheimer's Drug Fails Pivotal Study
These AI trades triggered this morning (545% return)
If you think a market crash is possible in 2024, I don't know why you're not using this yet.
Core Medalist ETFs
The Connor Phillips Show
Medivation Stock Hits New 52-Week High (MDVN)
Medivation (MDVN) Stock Surges, Will Explore Sale
See More Headlines
Receive MDVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (MDVN) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/09/2016
Today
4/26/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MDVN
CUSIP
58501N10
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

MDVN Stock Analysis - Frequently Asked Questions

How were (MDVN)'s earnings last quarter?

(MDVN) (NASDAQ:MDVN) released its quarterly earnings results on Tuesday, August, 9th. The biopharmaceutical company reported $0.29 EPS for the quarter, beating analysts' consensus estimates of $0.27 by $0.02. The biopharmaceutical company had revenue of $206 million for the quarter, compared to the consensus estimate of $214.52 million. The company's revenue for the quarter was up 17.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.58 EPS.

What other stocks do shareholders of (MDVN) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other (MDVN) investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and

This page (NASDAQ:MDVN) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners